Dr Piers Ingram, PhD, co-founder, and CEO of Singapore-based biotech Hummingbird Bioscience, shares his motivation for establishing the company in 2015, their proprietary Rational Antibody Discovery (RAD) technology platform, and rich pipeline of clinical assets in global development.
As we are able to now understand biological systems much better and leverage the countless advances in the technologies and tools that can enable us to build this understanding, biomedical research is definitely entering a golden era
